Opus Genetics (IRD) Capital Expenditures Growth (1y) (2011 - 2019)
Opus Genetics (IRD) Capital Expenditures Growth (1y) (2011 - 2019) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -37.81% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -34.23% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 22,433.30% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 142.64% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -73.62% |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 537.41% |
| Mar 31, 2019 | 423.06% |
| Sep 30, 2018 | 932.99% |
| Jun 30, 2018 | -93.02% |
| Mar 31, 2018 | -36.44% |
| Dec 31, 2017 | 13,249.63% |
| Sep 30, 2017 | 359.97% |
| Jun 30, 2017 | 378.39% |
| Mar 31, 2017 | -13.73% |
| Dec 31, 2016 | -95.89% |
| Sep 30, 2016 | -98.13% |
| Jun 30, 2016 | -34.54% |
| Mar 31, 2016 | -42.08% |
| Dec 31, 2015 | -11.64% |
| Sep 30, 2015 | 151.64% |
| Jun 30, 2015 | -57.36% |
| Mar 31, 2015 | 110.42% |
| Dec 31, 2014 | 200.68% |
| Sep 30, 2014 | -64.46% |
| Jun 30, 2014 | 944.30% |